Resmed (ASX:RMD) is down 4% halfway through Monday’s session after releasing its September quarter Form 10-Q this morning and headline 1Q26 result last Friday.
Resmed is dual-listed on the NYSE which is why it files the Form 10-Q.
The company delivered reported NPAT of US$374.9 million which was an increase of 15%. Notably, most of the financial results for the quarter met market expectations, which generally isn’t cause for a weak share price reaction. The company is trading at around 22.5x its FY26 normalised EPS.
Resmed’s Chairman and CEO, Mick Farrell said “We delivered 9% headline revenue growth year-over-year, with a very strong 280 basis points of non-GAAP gross margin expansion, resulting in double-digit bottom-line performance: 16% non-GAAP EPS growth. These results reinforce the success of our strategy to transform healthcare in the home with hardware, software and solutions that people love.”
